top of page
  • Active, not recruiting

NCT02316106: Phase 2 - A Study to Evaluate 3 Dose Schedules of Daratumumab in SMM - CENTAURUS

Updated: May 23, 2022


CENTAURUS


CENTAURUS

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

The purpose of this study is to evaluate three daratumumab dose schedules in participants with Smoldering Multiple Myeloma.


Sponsor

Janssen Research & Development, LLC


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT02316106


Official Title: A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma

First Posted : December 12, 2014


Click here to see details on ClinicalTrials.gov

 
 

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy.

Adv Ther. 2021 Feb

Click here to see details

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).

Leukemia. 2020 Jul

Click here to see details

 

Locations


United States, Arkansas

United States, Florida

United States, Georgia

United States, Massachusetts

United States, Michigan

United States, Missouri

United States, New Jersey

United States, New York

United States, North Carolina

United States, Ohio

United States, Pennsylvania

United States, Tennessee

United States, Washington


Canada, Alberta

Canada, Ontario


Europe

United Kingdom

Czechia

France

Germany

Netherlands

Russian Federation


Asia

Turkey

Israel


Australia




コメント


Posts Archive
bottom of page